Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald
CEO & Managing Director, Dr Tony Keating
Source: Courier Mail
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices
  • This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices
  • This testing was designed to ensure ResAppDx's algorithms had the required level of accuracy for each make and model of the phone
  • ResAppDx uses machine learning algorithms to analyse a patients cough sounds to diagnose disease and provide quick and accurate information
  • ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term
  • Company shares up 9.52 per cent on the market this morning and are trading for 11.5 cents each

ResApp Health (RAP) has launched its respiratory diagnostic test, ResAppDx, on select Android devices.

This launch follows thorough testing, and the app is now available on the Samsung Galaxy S9, S10 and S20 devices.

This testing was designed to ensure that ResAppDx's algorithms had the required level of accuracy for each make and model of the phone.

Multiple new testing procedures and algorithms were needed to ensure the test would be perform similar on each device.

ResApp is now in the process of launching ResAppDx for Android through its existing partners and further launches on other devices are planned for the near-term.

"Launching ResAppDx on select Android devices is a major achievement for ResApp. The company has undertaken extensive testing to ensure our offering continues to meet the high standards set by regulative bodies and provides clinicians with best in class solution to test for respiratory disease," CEO and Managing Director Dr Tony Keating said.

"We anticipate that the launch for Android users will considerably broaden our potential patient base and look forward to launching SleepCheck for Android," he added.

ResAppDx is ResApp's mobile software app which is used by clinicians for the diagnosis of multiple respiratory problems.

It uses machine learning algorithms to analyse a patient's cough sounds and diagnose the disease and provide quick and accurate information.

It is a software-only solution that runs on smartphones, meaning it does not require any additional hardware or accessories.

ResApp is up 9.52 per cent on the market this morning with shares trading for 11.5 cents each at 11:24 am AEDT.

RAP by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert - The Market Herald

" Rhythm Biosciences (ASX:RHYS) adds Sonic Clinical Services to ColoSTAT clinical trial

Rhythm Biosciences (RHY) has added the primary care division of medical giant Sonic Healthcare (SHL) to its ColoSTAT clinical trial.
Orthocell (ASX:OCC) - CEO Paul Anderson with intern Margeux Steltz - The Market Herald

" Orthocell (ASX:OCC) secures Chinese and NZ patents

Regenerative medicine company Orthocell (OCC) has secured Chinese and New Zealand patents for its novel CelGro collagen medical device for soft tissue regeneration.
Patrys (ASX:PAB) - - The Market Herald

" Study finds Patrys’ (ASX:PAB) candidate could slow brain cancer

A new study featuring Patrys’ (PAD) PAT-DX1 candidate has demonstrated its ability to inhibit the growth of primary and secondary brain cancers.
Avita Medical (ASX:AVH) - CEO, Mike Perry - The Market Herald

" Avita Medical (ASX:AVH) boosts fourth-quarter revenue forecast

With the prevailing strength of its RECELL System, Avita Medical (AVH) has elected to increase its fourth-quarter revenue guidance.